Skip to main
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals is expected to do well in 2026 and beyond, with potential growth in its Rare Disease and Brands businesses, as well as its Generics portfolio. Additionally, expected improvements in revenue from their Purified Cortrophin Gel, ILUVIEN, and YUTIQ products, as well as an overall increase in revenue, suggest a positive outlook for the company. However, there are potential risks such as unforeseen setbacks and challenges with the Alimera integration or in executing deals, and worsening pricing and competitive pressures in the generics industry.

Bears say

ANI Pharmaceuticals is experiencing a decrease in sales guidance for their key product, Cortrophin, due to weaker-than-expected performance in the first half of the year. Additionally, while prescription volumes for Cortrophin have reached all-time highs, this has not translated into significant revenue growth, leading to investor hesitation. However, the company's strong presence in the generics market and their expanding sales force present a potential for long-term growth.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.